Nexalis Therapeutics Limited has released a press release.
Quarterly Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Story so far
Earlier from Nexalis Therapeutics
- First Cohort Complete for Phase 1, Pain Indication IRX211
- First Patient Dosed for Phase 1, Pain Indication IRX211
- Ethics Approval for Phase 1 CRPS
- Contract Research Organisation Appointment
- Board and Management Changes
Later from Nexalis Therapeutics
- Quarterly Activities Report
- Sep23 Appendix 4C
- Sep23 Quarterly Activities Report
- Significant Milestone - Completion of IRX211 Phase 1 Trial
- IRX211 - Targeted Pain Indication Nomination - BTcP
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics